Key result
Long-term treatment with gliclazide significantly reduced mean platelet adhesiveness in patients with maturity onset diabetes from 29% at baseline to 19.5% after 1 year (p<0.001).
Why the study?
Does gliclazide reduce platelet adhesiveness in patients with maturity onset diabetes?
Observational (n=50)
Does gliclazide reduce platelet adhesiveness in patients with maturity onset diabetes?
Absolute Event Rate: 19.5% vs 29%
p-value: p=<0.001
Long-term treatment with gliclazide significantly reduces platelet adhesiveness in patients with maturity-onset diabetes without impairing normal hemostasis.
May support antiplatelet effects in maturity-onset diabetes; hypothesis-generating and requires randomized outcome trials before practice change.
Gliclazide is an oral hypoglycaemic agent which has been shown in animal models to reduce platelet adhesiveness. In this study, 50 patients with maturity onset diabetes treated with gliclazide (80 mg/day) were followed up for 6 months to 1 year to assess the effect on platelet adhesiveness and control of blood sugar. A significant fall in mean platelet adhesiveness from 29% before treatment to 19.5% after 1 year (p less than 0.001) was achieved without any deleterious effect on normal haemostasis. The drug was well tolerated and achieved a satisfactory control of blood sugar levels at the dosages used.
No takes yet. Share an insight, caveat, or question.
Rubinjoni et al. (1978) conducted an observational in Maturity onset diabetes (n=50). Gliclazide vs. Baseline (before treatment) was evaluated on Platelet adhesiveness (p=<0.001). Long-term treatment with gliclazide significantly reduced mean platelet adhesiveness in patients with maturity onset diabetes from 29% at baseline to 19.5% after 1 year (p<0.001).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: